Nuclear Medicine Imaging of Prostate Cancer

Nuclear Medicine Imaging of Prostate Cancer Nuklearmedizinische Diagnostik des Prostatakarzinoms

Correspondence Dr. Vera Schreiter Radiology, Charité Universitätsmedizin Berlin Augustenburger Platz 1 13353 Berlin Germany Tel.: ++ 49/30/4 506571 65 Fax: ++ 49/30/5279 94 [email protected] Introduction ▼ The use of gallium-68 (Ga-68)-labeled prostate-specific membrane antigen (PSMA) ligands for the diagnosis of prostate cancer is a promising innovation for the metabolic imaging of pro...

Nuclear Medicine Imaging in Cancer

The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with co...

Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology

The bone scan continues to be recommended for both the staging and therapy response assessment of skeletal metastases from prostate cancer. However, it is widely recognised that bone scans have limited sensitivity for disease detection and is both insensitive and non-specific for determining treatment response, at an early enough time point to be clinically useful. We, therefore, review the evo...

depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging

context inherited and sporadic medullary thyroid cancer (mtc) is an uncommon and medically challenging malignancy. even if the extent of initial surgery is deemed adequate, the recurrence rate remains high, up to 50% in most series. measurement of serum calcitonin is important in the follow-up of patients with mtc, and reliably reflects the existence of the disease. evidence acquisition there i...